Table 2.
Current clinical targets of CAR-T therapy for hematological malignancies (ClinicalTrials.gov).
| Target | Disease | Stage | Phase | NCT number | Country |
|---|---|---|---|---|---|
| CD19 | Refractory CD19+ lymphoma and leukemia | Completed | I | NCT01626495 | United States |
| B-cell leukemia or lymphoma | I | NCT01029366 | United States | ||
| Refractory B cell malignancy | I/II | NCT02132624 | Sweden | ||
| B cell leukemia or lymphoma | I | NCT01593696 | United States | ||
| ALL | I | NCT01551043 | United States | ||
| Resistant or refractory CD19+ ALL | I | NCT02975687 | China | ||
| Resistant or refractory CD19+ ALL | II | NCT02030847 | United States | ||
| CD19 + CD22 |
Relapsed or refractory lymphoma and leukemia | Recruiting | I/II | NCT03398967 | China |
| CD19 positive diffuse large B-cell lymphoma or B ALL | I | NCT03233854 | United States | ||
| CD19 +CD22+ leukemia | I | NCT03330691 | United States | ||
| Refractory and/or Recurrent B cell malignancies | I/II | NCT03098355 | China | ||
| Children or young adults with CD19 positive B ALL | I | NCT03241940 | United States | ||
| B-cell ALL | I/II | NCT03614858 | China | ||
| B-cell ALL | I/II | NCT03289455 | United Kingdom | ||
| B-cell hematologic malignancy | I/II | NCT02903810 | China | ||
| CD19/CD22-expressing B cell malignancies | I | NCT03448393 | United States | ||
| CD19 + CD20 | Relapsed or refractory lymphoma and leukemia | Recruiting | I/II | NCT03398967 | China |
| CD22 | CD22+ leukemia and lymphoma | Active | I | NCT03244306 | United States |
| Chemotherapy resistant or refractory ALL | Terminated | I | NCT02588456 | United States | |
| B cell malignancies | Recruiting | I/II | NCT02935153 | China | |
| B cell malignancies | Recruiting | I/II | NCT03262298 | China | |
| ALL | Recruiting | I | NCT03620058 | United States | |
| ALL | Recruiting | I | NCT02650414 | United States | |
| CD20 | Refractory or relapsed B lymphocyte lymphoma | Recruiting | I | NCT03576807 | China |
| B cell malignancies | Recruiting | I/II | NCT02710149 | China | |
| Relapsed or refractory B cell non-Hodgkin lymphomas | Recruiting | I/II | NCT03277729 | United States | |
| ROR1R | ROR1+ malignancies | Recruiting | I | NCT02706392 | United States |
| CLL | Withdrawn | I | NCT02194374 | United States | |
| CD4 | CD4+ lymphoma and leukemia | Recruiting | I | NCT03829540 | United States |
| CD7 | High risk T cell malignancies | NR | I | NCT03690011 | United States |
| CD38 | Relapsed B-cell ALL after anti-CD19 CAR-T therapy | Recruiting | I/II | NCT03754764 | China |
| CD30 | Lymphocyte malignancies | Recruiting | I/II | NCT02958410 | China |
| Hodgkin lymphoma, adult | NA | – | NCT03914885 | United States | |
| BCMA | High-risk multiple myeloma | Recruiting | I/II | NCT03455972 | China |
| B-cell lymphoma and leukemia | Recruiting | I/II | NCT02954445 | China |
CLL, chronic lymphocytic leukemia; ROR1R, receptor tyrosine kinase-like orphan receptor; NA, not available; NR, not yet recruiting.